Portuguese Registry on Interventional Cardiology

Overview

The purpose of this Registry is creating a database management that allows continuous monitoring characteristics, evolution, prognostic indicators and management of patients undergoing coronary angioplasty in Portuguese Hospitals, and identify the appropriateness of clinical and interventional practice recommendations for diagnosis and treatment of coronary disease and monitoring its evolution.

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2018

Detailed Description

Cardiovascular disease remains the main cause of death in Portugal and approximately one quarter of these are directly to ischemic heart disease. In order to better characterize percutaneous coronary intervention in Portugal, the Portuguese Society of Cardiology has promoted the Portuguese registry on percutaneous coronary intervention. This will include all adult patients (≥ 18 years), eligible for percutaneous coronary intervention (PCI) in accordance with PCI state-of-art recommendations (including unstable and stable coronary disease). The Cardiology department where the patient has been hospitalized is responsible for the patient inclusion in the study. Excluded patients are those in whom the preferred treatment is Coronary Artery Bypass Graft (CABG), age under 18 years or life expectancy of less than 12 months.

Clinical Trial Outcome Measures

Primary Measures

  • Major adverse cardiac event rate (MACE) MACE: A composite of all cause death, documented Myocardial Infarction (MI), unplanned hospitalization leading to urgent revascularization.
    • Time Frame: 24 months

Secondary Measures

  • Total mortality
    • Time Frame: 12 month
    • Total mortality at 12 month

Participating in This Clinical Trial

Inclusion Criteria

1. Patients with:

  • stable angina or, – stabilized angina pectoris or, – atypical chest pain or, – no chest pain but with documented silent ischemia 2. At least one stenosis is present of at least 50% in one major native epicardial coronary artery and supplying viable myocardium 3. Eligible for PCI 4. Informed consent Exclusion Criteria:

1. Patients in whom the preferred treatment is CABG; 2. Contra-indication to dual antiplatelet therapy 3. Coronary artery disease precluding PCI 4. A life expectancy of less than 1 year 5. Age under 21

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Portuguese Society of Cardiology
  • Collaborator
    • Portuguese Association of Interventional Cardiology
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marco Costa, MD, Principal Investigator, Portuguese Society of Cardiology
  • Overall Contact(s)
    • Sandra M Corker, 00351 239 838 101, sandra.corker@spc.pt

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.